Abstract
Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Letters in Drug Design & Discovery
Title: Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy
Volume: 2 Issue: 7
Author(s): Marco L. Rossi, Dennis Zavalloni, Guido Belli and Patrizia Presbitero
Affiliation:
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Abstract: Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Export Options
About this article
Cite this article as:
Rossi L. Marco, Zavalloni Dennis, Belli Guido and Presbitero Patrizia, Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy, Letters in Drug Design & Discovery 2005; 2 (7) . https://dx.doi.org/10.2174/157018005774479168
DOI https://dx.doi.org/10.2174/157018005774479168 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of the Giant Elastic Protein Titin in the Frank-Starling Mechanism of the Heart
Current Vascular Pharmacology The Impact of Variable Factors on the Health-Related Quality of Life in the Elderly in Japan and Russia
Current Aging Science Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery Emerging Promise of Therapeutic Approaches Targeting Mitochondria in Neurodegenerative Disorders
Current Neuropharmacology Meet Our Editorial Board Member
Current Cardiology Reviews Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension
Current Hypertension Reviews Proximate Composition and Mineral Content of Some Cameroonian Traditional Sauc es Prepared from Red Sorrel Leaves (H ibiscus sabdariffa L.)
Current Nutrition & Food Science Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews PCSK9 A/G (rs505151) Gene Polymorphism and its Expression at the Molecular Level in Patients with Coronary Artery Disease
Current Pharmacogenomics and Personalized Medicine Adrenomedullin in the Kidney-Renal Physiological and Pathophysiological Roles
Current Medicinal Chemistry Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Antithrombotic Therapy After TAVR
Current Vascular Pharmacology Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation
Current Vascular Pharmacology Effects of Cyclosporine A and Itraconazole on Permeability, Biliary Excretion and Pharmacokinetics of Amlidipine
Drug Metabolism Letters The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science Antihypertensive Properties of Angiotensin-Converting Enzyme Inhibitors (ACEI) Independent of the Renin-Angiotensin System
Current Hypertension Reviews Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews